Matthew Rehmann
About Matthew Rehmann
Matthew Rehmann is a scientist at Bristol Myers Squibb in New York, specializing in upstream process analytical technology and bioprocessing.
Company
Matthew Rehmann currently works at Bristol Myers Squibb in New York, New York, United States. Bristol Myers Squibb is a globally recognized biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. His role involves working as a scientist specializing in upstream process analytical technology, with a focus on Raman and capacitance techniques.
Title
Matthew Rehmann holds the title of Scientist at Bristol Myers Squibb. His responsibilities include developing and optimizing bioreactor processes for cell culture, employing advanced analytical tools and techniques to enhance process efficiency and product quality. His expertise is instrumental in the process development and intensification efforts of the company’s biopharmaceutical production.
Education and Expertise
Matthew Rehmann earned a Doctor of Philosophy (Ph.D.) from the University of Delaware, where he studied from 2010 to 2016. Additionally, he holds a Bachelor of Science in Engineering from the University of Pennsylvania, completed between 2006 and 2010. His scientific expertise includes upstream process analytical technology (PAT), focussing on Raman and capacitance techniques, statistical design of experiments, and data analytics for bioprocessing. He is also skilled in various biochemical cell analysis techniques such as immunocytochemistry, quantitative RT-PCR, and flow cytometry.
Background
Matthew Rehmann has a robust background in the biopharmaceutical industry, with 5 years of experience in process development. Prior to his current role at Bristol Myers Squibb, he worked as a Research Assistant in the April Kloxin Group at the University of Delaware for six years. His experience spans cell culture process development, process intensification, bioreactor scale-up, and scale-down processes, making significant contributions to bioprocessing advancements.